Full Press Release Details
CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients
CareDx Files Second Lawsuit Against Natera
BRISBANE, Calif., April 10, 2019 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on
creating diagnostic solutions for organ transplant patients, has filed a second lawsuit against Natera, Inc. in the United States District Court for Delaware. In this suit, CareDx alleges that Natera s comparisons of its kidney transplant
technology to CareDx s AlloSure technology are based on numerous unscientific, unreliable, and inappropriate conclusions, and are therefore misleading.
Natera has begun a false advertising campaign designed to deceive doctors, healthcare professionals, insurance companies, and patients as well as
investors into believing that Natera s me too test is superior to AlloSure when that has simply not been shown, says CareDx in its complaint. The complaint states several times that the comparisons to AlloSure are false
both because the Natera Study is substantially flawed and because the Natera and CareDx study methodologies differ so significantly that comparison claims are precluded.
The complaint points to four specific examples of why Natera s comparisons of its product to AlloSure are unfair and inappropriate:
Just one of these four instances could be chalked up to innocent mistake or unintentional error, said CareDx attorney Ed Reines of Weil,
Gotshal & Manges LLP. However, together they suggest a concerted effort by Natera to mislead patients and medical personnel into thinking its study was more credible than it actually was and that it proved Natera s technology is
superior to CareDx s, which it is not.
CareDx is seeking all available remedies, including monetary damages.
CareDx, Inc., headquartered in
Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com.
Integrated Corporate Relations, Inc.